Wechselwirkungen · Potactasol
Potactasol 1 mg powder for concentrate for solution for infusion Potactasol 4 mg powder for concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 5
HOS-214133 · Präparat HOS-155272
When combining topotecan with other chemotherapy agents, reduction of the doses of each medicinal product may be required to improve tolerability. However, when combining with platinum agents, there is a distinct sequence-dependent interaction depending on whether the platinum agent is given on day 1 or 5 of the topotecan dosing. If either cisplatin or carboplatin is given on day 1 of the topotecan dosing, a lower dose of each agent must be given to improve tolerability compared to the dose of each agent which can be given if the platinum agent is given on day 5 of the topotecan dosing.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): platinum (HOS-086055) cisplatin (HOS-086022) carboplatin (HOS-084540)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-01-20T15:29:00Z · SHA-256 c68b2e48aa64589388567936c88f944172f5a013496cba099e51d86c2816bef9 · Passage 58d81a57b11ead3d73eb33334eb39df9103c652bbe12accd485c9d2a8c4e085a · Zeichen 386–979 im Abschnitt